Neomics Pharmaceuticals

Recent Finacing

Pre-Series A

Recent Raise

Undisclosed

NEOMICS develops tumor-targeting polyclonal T cell receptors and multi-clonal TCR-based cell therapies for solid tumors, operating R&D in Shanghai and an innovation hub in Maryland, U.S.